JPRN-UMIN000040859已完成未知
Activation status of eosinophils in severe asthma patients treated with biologics - ACT study
Department of respiratory medicine, University of Tsukuba Hospital0 个研究点目标入组 27 人开始时间: 2020年7月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 27
研究概览
简要总结
We evaluated the variation in gene expression profiles of peripheral blood eosinophils before and after starting treatment with mepolizumab. The expression of genes associated with IL-5/IL-5R signaling was decreased in eosinophils of patients treated with mepolizumab compared to that before starting mepolizumab. In contrast, genes particularly associated with type 1 eosinophils were upregulated after treatment with mepolizumab.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Exclusion criteria for all participant group 1. Concurrent Respiratory Disease: Presence of a known pre-existing, clinically important lung condition other than asthma. 2. Malignancy: A current malignancy or previous history of cancer in remission for less than 12 months prior to screening. 3. Liver Disease: Known, pre-existing, unstable liver disease. 4. Cardiovascular: Subjects who have severe or clinically significant cardiovascular disease uncontrolled with standard treatment. 5. Other Concurrent Medical Conditions: Subjects who have known, pre-existing, clinically significant endocrine, autoimmune, metabolic, neurological, renal, gastrointestinal, hepatic, haematological or any other system abnormalities that are uncontrolled with standard treatment. 6. Eosinophilic Diseases: Subjects with other conditions that could lead to elevated eosinophils such as hyper-eosinophilic syndrome, Churg-Strauss syndrome, or eosinophilic esophagitis. 7. Pregnancy: Subjects who are pregnant or breastfeeding. Specific exclusion criteria for each group Participant group 3 (N = 3 for each biologic, total N=9), 1. Participants who have received any biologics (mepolizumab, omalizumab, benralizumab, or dupilumab) within 56 days before Visit 1.
研究者
相似试验
已完成
不适用
BIOmarkers in Severe AsthMa Patients on Omalizumab TreatmentSevere AsthmaNCT03361111Medical University of Warsaw16
Unknown
4 期
Flow Cytometry Analysis of Eosinophils in Severe Asthma Patients.Severe AsthmaNCT05001529Scarlata, Simone, M.D.80
Unknown
不适用
The Clinical Profile of UK Asthma Patients With Raised Blood EosinophilsAsthmaNCT02140541Research in Real-Life Ltd130,248
Unknown
不适用
Non-coding RNAs Analysis of Eosinophil Subtypes in AsthmaSevere Eosinophilic AsthmaAllergic AsthmaNCT04542902Lithuanian University of Health Sciences80
已完成
不适用
Intense Airway Eosinophilia in AsthmaEosinophilic AsthmaAsthmaNCT03696914Laval University918